1984-09 to 1989-07 Bachelor of Medicine: Anhui Medical University
1992-09 to 1995-07 Master of Psychiatry: Peking University Institute of Mental Health
1995-09 to 1998-07 Doctorate in Psychiatry: Peking University Institute of Mental Health
1999-08 to 2000-07 Postdoctoral Research: Rutgers University
2000-08 to 2003-07 Postdoctoral Research: Yale University School of Medicine
1989-08 to 1994-08 Beijing Huilongguan Hospital - Clinical Psychology Department - Resident Physician
1995-09 to 1999-08 Beijing Huilongguan Hospital - Clinical Psychology Department - Attending Physician (Deputy Director/Branch Secretary)
2003-08 to 2006-07 Yale University School of Medicine - Department of Psychiatry - Associate Research Scientist
2006-08 to 2009-07 Baylor College of Medicine - Department of Psychiatry - Assistant Professor
2009-08 to 2014-07 Baylor College of Medicine - Department of Psychiatry - Associate Professor
2014-08 to 2018-02 University of Texas Health Science Center at Houston - Department of Psychiatry - Associate Professor/Attending Physician
2018-03 to Present Institute of Psychology, Chinese Academy of Sciences - Health and Genetic Psychology Laboratory - Researcher
2008: Second Prize of Beijing Science and Technology Achievements
2006: Senior Scientist Award at the 13th Schizophrenia Symposium, Davos, Switzerland
2006: Young Psychiatrist Award by the World Psychiatric Association, Istanbul, Turkey
2005: Young Investigator Award by the American College of Neuropsychopharmacology and National Institute of Mental Health, Hawaii, USA
2005: Young Scientist Travel Award at the 66th American Society of Addiction Medicine, Florida, USA
2004: Young Investigator Award at the 7th International Congress of Neuroimmunology, Venice, Italy
2003: National Institute on Drug Abuse Young Scientist Award at the 64th American Society of Addiction Medicine, Florida, USA
2000: Young Scientist Award at the 10th Schizophrenia Symposium, Davos, Switzerland
1998: First Prize of Janssen Library Excellent Paper by the Chinese Society of Psychiatry, Beijing, China
1996: Beijing Science and Technology New Star Program
1996: Second Prize of Excellent Paper by the Chinese Medical Association and Chinese Society of Neurology and Psychiatry, Beijing, China
1995: Second Prize of Beijing Health Bureau Science and Technology Achievements
1993: Second Prize of Beijing Health Bureau Science and Technology Achievements
1992: Second Prize of Excellent Paper by the Ministry of Health and Chinese Medical Association at the 7th Young and Middle-aged Physicians Conference
Research
Clinical psychological therapy and counseling Cognitive function research in mental disorders Big data and precision medicine research in psychiatry Relationship between smoking and mental disorders Free radical metabolism in mental disorders Immune function in mental disorders Genetics of mental disorders Neurotrophic factor research in mental disorders Neurophysiological research in mental disorders Nuclear magnetic resonance research in mental disorders Clinical psychopharmacology research in mental disorders: clinical efficacy and three major drug side effects (tardive dyskinesia, diabetes, and obesity)
Association between hippocampal subfields and clinical symptoms of first-episode and drug naive schizophrenia patients during 12 weeks of risperidone treatment., Lang X, Wang D, Chen D, Xiu M, Zhou H, Wang L, Cao B, Zhang XY., 2022
Altered antioxidant defenses in drug-naive first episode patients with schizophrenia are associated with poor treatment response to risperidone: 12-week results from a prospective longitudinal study., Li XR, Xiu MH, Guan XN, Wang YC, Wang J, Leung E, Zhang XY., 2021
Sex-specific association between antioxidant defense system and therapeutic response to risperidone in schizophrenia: a prospective longitudinal study., Liu H, Liu H, Jiang S, Su L, Lu Y, Chen Z, Li X, Li X, Wang X, Xiu M, Zhang X., 2021
Antioxidant enzymes and weight gain in drug-naive first episode schizophrenia patients treated with risperidone for 12 weeks: a prospective longitudinal study., Liu H, Yu R, Gao Y, Li X, Guan X, Thomas K, Xiu M, Zhang X., 2021
Glucose disturbances, cognitive deficits and white matter abnormalities in first-episode drug-naive schizophrenia., Zhang XY, Yang M, Du X, Liao W, Chen D, Fan F, Xiu M, Jia Q, Ning Y, Huang X, Wu F, Soares JC, Cao B, Wang L, Chen H., 2020
Treatment response prediction and individualized identification of first-episode drug-naive schizophrenia using brain functional connectivity., Cao B, Cho RY, Chen D, Xiu M, Wang L, Soares JC, Zhang XY., 2020
Sex-specific association between peripheral superoxide dismutase, BDNF and cognitive impairment in drug-naive first episode patients with schizophrenia., Qu M, Wang J, Chen DC, Chen S, Xiu MH, Zhang XY., 2020
Interrelationships between BDNF, superoxide dismutase and cognitive impairment in first episode drug-naive patients with schizophrenia., Xiu MH, Li Z, Curbo ME, Wu HE, Chen DC, Chen S, Tong YS, Tan SP, Zhang XY., 2020
Cognitive enhancing effect of high-frequency neuronavigated rTMS in chronic schizophrenia patients with predominant negative symptoms: A double-blind controlled 32-week follow-up study., Xiu MH, Guan HY, Zhao JM, Wang KQ, Pan YF, Su XR, Wang YH, Guo JM, Jiang L, Liu HY, Sun SG, Wu HR, Liu XW, Yu HJ, Wei BC, Li XP, Trinh T, Tan SP, Zhang XY., 2020
One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia., Xia L, Liu L, Hong X, Wang D, Wei G, Wang J, Zhou H, Xu H, Tian Y, Dai Q, Wu HE, Chang C, Wang L, Kosten TR, Zhang XY., 2020
Sex differences in the prevalence and clinical features of comorbid depressive symptoms in patients with never-treated, first-episode schizophrenia., Wang DM, Zhang XY., 2019
Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia: relationships to clinical phenotypes and cognitive deficits., Chen DC, Yang KB, Nie Y, Wang N, Li YL, Xiu MH, He SC, Yang FD, Kosten TR, Soares JC, Zhang XY., 2016
Contribution of IL-10 and its -592 A/C polymorphism to cognitive functions in first-episode drug-naive schizophrenia., Xiu MH, Tian L, Chen S, Tan YL, Chen DC, Chen J. Chen N, Yang FD, Licinio J, Kosten TR. Soares JC, Zhang XY., 2016
Interaction of BDNF with cytokines in chronic schizophrenia., Zhang XY, Tan YL, Chen DC, Tan SP, Yang FD, Wu HE, Zunta-Soares GB, Kosten TR, Huang XF, Soares JC., 2016
Cognitive function, plasma manganese superoxide dismutase (MnSOD) and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls., Zhang XY, Chen da C, Xiu MH, Yang FD, Tan YL, Luo X, Zuo L, Kosten TA, Kosten TR., 2014
Cigarette smoking, psychopathology, and cognitive function in first-episode drug naive schizophrenia: a case-control study., Zhang XY, Chen da C, Xiu MH, Haile CN, Luo X, Zuo L, Kosten TA, Kosten TR., 2013
Interleukin 18 and cognitive impairment in first episode and drug naive schizophrenia versus healthy controls., Zhang XY, Tang W, Xiu MH, Chen DC, De Yang F, Tan YL, Wang ZR, Zhang F, Liu J, Liu L, Chen Y, Wen N, Kosten TR., 2013
Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia., Zhang XY, Liu L, Liu S, Hong X, Chen DC, Xiu MH, Kosten TA, Kosten TR., 2012
Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba., Zhang XY, Chen DC, Xiu MH, Haile CN, Zhang HP, Luo X, Xu K, Kosten TA, Kosten TR., 2012
Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia., Zhang XY, Tan YL, Zhou DF, Haile CN, Wu GY, Cao LY, Kosten TA, Kosten TR., 2007
Nicotine dependence, symptoms, and oxidative stress in male patients with schizophrenia., Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Haile CN, Kosten TA, Kosten TR., 2007
Previous exposure to cocaine enhances cocaine self-administration in an alpha 1-adrenergic receptor dependent manner., Zhang XY, Kosten TA., 2007
Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking., Zhang XY, Kosten TA., 2005
Tumour necrosis factor alpha polymorphism (-1031T/C) is associated with age of onset of schizophrenia., Zhang XY, Haile CN, Tan YL, Zuo LJ, Yang BZ, Cao LY, Zhou DF., 2005
Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics., Zhang XY, Zhou DF, Cao LY, Wu GY, Shen YC., 2005
